A small chimeric promoter for high prostate-specific transgene expression from adenoviral vectors

Prostate

Volumn 67, Issue 8, 2007, Pages 829-839

  Kraaij, Robert ^a,b   Van Der Weel, Laura ^a   De Ridder, Corrina M A ^a   Van Der Korput, Hetty A G M ^a   Zweistra, Joke L M ^a   Van Rijswijk, Angélique L C T ^a   Bangma, Chris H ^a   Trapman, Jan ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

Adenovirus; Gene therapy; Mouse model; Prostate cancer; Transcriptional targeting

Indexed keywords

ADENOVIRUS VECTOR; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CHIMERA; CYTOMEGALOVIRUS; ENHANCER REGION; GENE EXPRESSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR CLONING; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; SAFETY; TRANSCRIPTION REGULATION; TRANSGENE;

ADENOCARCINOMA; ADENOVIRIDAE; ANDROGEN-BINDING PROTEIN; ANIMALS; CELL LINE, TUMOR; CYTOMEGALOVIRUS; GENE THERAPY; GENETIC VECTORS; HUMANS; MALE; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; PLASMIDS; PROMOTER REGIONS (GENETICS); PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECOMBINANT FUSION PROTEINS; TRANSGENES;

EID: 34249670092     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20560     Document Type: Article

References (38)

1. Coffey DS. Prostate cancer. An overview of an increasing dilemma. Cancer 1993;71:880-886.
2. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
3. Post LE. Selectively replicating adenoviruses for cancer therapy: An update on clinical development. Curr Opin Investig Drugs 2002;3:1768-1772.
4. Reid T, Warren R, Kirn D. Intravascular adenoviral agents in cancer patients: Lessons from clinical trials. Cancer Gene Ther 2002;9:979-986.
5. Steiner MS, Gingrich JR, Chauhan RD. Prostate cancer gene therapy. Surg Oncol Clin N Am 2002;11:607-620.
6. Kubo H, Gardner TA, Wada Y, Koeneman KS, Gotoh A, Yang L, Kao C, Lim SD, Amin MB, Yang H, Black ME, Matsubara S, Nakagawa M, Gillenwater JY, Zhau HE, Chung LW. Phase 1 dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther 2003;14:227-241.
7. Pramudji C, Shimura S, Ebara S, Yang G, Wang J, Ren C, Yuan Y, Tahir SA, Timme TL, Thompson TC. In situ prostate cancer gene therapy using a novel adenoviral vector regulated by the caveolin-1 promoter. Clin Cancer Res 2001;7:4272-4279.
8. Gotoh A, Ko SC, Shirakawa T, Cheon J, Kao C, Miyamoto T, Gardner TA, Ho LJ, Cleutjens CB, Trapman J, Graham FL, Chung LW. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer. J Urol 1998;160:220-229.
9. Lu Y, Steiner MS. Transcriptionally regulated adenoviruses for prostate-specific gene therapy. World J Urol 2000;18:93-101.
10. Zhang J, Thomas TZ, Kasper S, Matusik RJ. A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology 2000;141:4698-4710.
11. van der Poel HG, McCadden J, Verhaegh GW, Kruszewski M, Ferrer F, Schalken JA, Carducci M, Rodriguez R. A novel method for the determination of basal gene expression of tissue-specific promoters: An analysis of prostate-specific promoters. Cancer Gene Ther 2001;8:927-935.
12. Lee SJ, Kim HS, Yu R, Lee K, Gardner TA, Jung C, Jeng MH, Yeung F, Cheng L, Kao C. Novel prostate-specific promoter derived from PSA and PSMA enhancers. Mol Ther 2002;6:415-421.
13. Martiniello-Wilks R, Tsatralis T, Russell P, Brookes DE, Zandvliet D, Lockett LJ, Both GW, Molloy PL, Russell PJ. Transcription-targeted gene therapy for androgen-independent prostate cancer. Cancer Gene Ther 2002;9:443-452.
14. Cheng WS, Giandomenico V, Pastan I, Essand M. Characterization of the androgen-regulated prostate-specific T cell receptor gamma-chain alternate reading frame protein (TARP) promoter. Endocrinology 2003;144:3433-3440.
15. Cheng WS, Kraaij R, Nilsson B, van der Weel L, de Ridder CM, Totterman TH, Essand M. A novel TARP-promoter-based adenovirus against hormone-dependent and hormone-refractory prostate cancer. Mol Ther 2004;10:355-364.
16. Zeng H, Wu Q, Li H, Wei Q, Lu Y, Li X, Wang F, Zhao F, Ding Z, Yang Y. Construction of prostate-specific expressed recombinant plasmids with high transcriptional activity of prostate-specific membrane antigen (PSMA) promoter/enhancer. J Androl 2005;26:215-221.
17. Chapel-Fernandes S, Jordier F, Lauro F, Maitland N, Chiaroni J, de Micco P, Mannoni P, Bagnis C. Use of the PSA enhancer core element to modulate the expression of prostate- and non-prostate-specific basal promoters in a lentiviral vector context. Cancer Gene Ther 2006;13:919-929.
18. Berthon P, Cussenot O, Hopwood L, Le Duc A, Maitland NJ. Functional expression of SV40 in normal human prostatic epithelial and fibroblastic cells: Differentiation pattern of non-tumorigenic cell lines. Int J Oncol 1995;6:333-343.
19. Marques RB, van Weerden WM, Erkens-Schulze S, de Ridder CM, Bangma CH, Trapman J, Jenster G. The human PC346 xenograft and cell line panel: A model system for prostate cancer progression. Eur Urol 2006;49:245-257.
20. Marques RB, Erkens-Schulze S, de Ridder CM, Hermans KG, Waltering K, Visakorpi T, Trapman J, Romijn JC, van Weerden WM, Jenster G. Androgen receptor modifications in prostate cancer cells upon long-termandrogen ablation and antiandrogen treatment. Int J Cancer 2005;117:221-229.
21. Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu SM, Johnston D, Pollack A, Pathak S, von Eschenbach AC, Logothetis CJ. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res 1997;3:2493-2500.
22. Lee YG, Korenchuk S, Lehr J, Whitney S, Vessela R, Pienta KJ. Establishment and characterization of a new human prostatic cancer cell line: DuCaP. In Vivo 2001;15:157-162.
23. Masters JR, Hepburn PJ, Walker L, Highman WJ, Trejdosiewicz LK, Povey S, Parkar M, Hill BT, Riddle PR, Franks LM. Tissue culture model of transitional cell carcinoma: Characterization of twenty-two human urothelial cell lines. Cancer Res 1986;46:3630-3636.
24. van Dijk MA, van Schaik FM, Bootsma HJ, Holthuizen P, Sussenbach JS. Initial characterization of the four promoters of the human insulin-like growth factor II gene. Mol Cell Endocrinol 1991;81:81-94.
25. Cleutjens KB, van Eekelen CC, van der Korput HA, Brinkmann AO, Trapman J. Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J Biol Chem 1996;271:6379-6388.
26. Cleutjens KB, van der Korput HA, Ehren-van Eekelen CC, Sikes RA, Fasciana C, Chung LW, Trapman J. A 6-kb promoter fragment mimics in transgenic mice the prostate-specific and androgen-regulated expression of the endogenous prostate-specific antigen gene in humans. Mol Endocrinol 1997;11:1256-1265.
27. Cleutjens KB, van der Korput HA, van Eekelen CC, van Rooij HC, Faber PW, Trapman J. An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol Endocrinol 1997;11:148-161.
28. Rembrink K, Romijn JC, van der Kwast TH, Rubben H, Schroder FH. Orthotopic implantation of human prostate cancer cell lines: A clinically relevant animal model for metastatic prostate cancer. Prostate 1997;31:168-174.
29. Kraaij R, van Weerden WM, de Ridder CMA, Gussenhoven EJ, Honkoop J, Nasu Y, Bangma CH. Validation of transrectal ultrasonographic volumetry for orthotopic prostate tumours in mice. Lab Anim 2002;36:165-172.
30. Babiss LE, Friedman JM, Darnell JE Jr. Cellular promoters incorporated into the adenovirus genome: Effects of viral regulatory elements on transcription rates and cell specificity of albumin and beta-globin promoters. Mol Cell Biol 1986;6:3798-3806.
31. Addison CL, Hitt M, Kunsken D, Graham FL. Comparison of the human versus murine cytomegalovirus immediate early gene promoters for transgene expression by adenoviral vectors. J Gen Virol 1997;78:1653-1661.
32. Steinwaerder DS, Lieber A. Insulation from viral transcriptional regulatory elements improves inducible transgene expression from adenovirus vectors in vitro and in vivo. Gene Ther 2000;7:556-567.
33. Rubinchik S, Lowe S, Jia Z, Norris J, Dong J. Creation of a new transgene cloning site near the right ITR of Ad5 results in reduced enhancer interference with tissue-specific and regulatable promoters. Gene Ther 2001;8:247-253.
34. Shi CX, Hitt M, Ng P, Graham FL. Superior tissue-specific expression from tyrosinase and prostate-specific antigen promoters/enhancers in helper-dependent compared with first-generation adenoviral vectors. Hum Gene Ther 2002;13:211-224.
35. Rennie PS, Bruchovsky N, Leco KJ, Sheppard PC, McQueen SA, Cheng H, Snoek R, Hamel A, Bock ME, MacDonald BS. Characterization of two cis-acting DNA elements involved in the androgen regulahon of the probasin gene. Mol Endocrinol 1993;7:23-36.
36. Greenberg NM, DeMayo FJ, Sheppard PC, Barrios R, Lebovitz R, Finegold M, Angelopoulou R, Dodd JG, Duckworth ML, Rosen JM, et al. The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Mol Endocrinol 1994;8:230-239.
37. Wolfgang CD, Essand M, Vincent JJ, Lee B, Pastan I. TARP: A nuclear protein expressed in prostate and breast cancer cells derived from an alternate reading frame of the T cell receptor gamma chain locus. Proc Natl Acad Sci USA 2000;97:9437-9442.
38. Andriani F, Nan B, Yu J, Li X, Weigel NL, McPhaul MJ, Kasper S, Kagawa S, Fang B, Matusik RJ, Denner L, Marcelli M. Use of the probasin promoter ARR2PB to express Bax in androgen receptor-positive prostate cancer cells. J Natl Cancer Inst 2001;93:1314-1324.